# Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus

> **NCT00057304** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 190 (actual)

## Conditions studied

- Diabetes

## Interventions

- **DRUG:** RO 205-2349

## Key facts

- **NCT ID:** NCT00057304
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2004-03
- **Final completion:** 2004-03
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2023-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00057304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00057304, "Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00057304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*